Management of chronic pain associated with temporomandibular disorders: a clinical practice guideline.
Abstract
[CLINICAL QUESTION] What is the comparative effectiveness of available therapies for chronic pain associated with temporomandibular disorders (TMD)?
[CURRENT PRACTICE] TMD are the second most common musculoskeletal chronic pain disorder after low back pain, affecting 6-9% of adults globally. TMD are associated with pain affecting the jaw and associated structures and may present with headaches, earache, clicking, popping, or crackling sounds in the temporomandibular joint, and impaired mandibular function. Current clinical practice guidelines are largely consensus-based and provide inconsistent recommendations.
[RECOMMENDATIONS] For patients living with chronic pain (≥3 months) associated with TMD, and compared with placebo or sham procedures, the guideline panel issued: (1) strong recommendations in favour of cognitive behavioural therapy (CBT) with or without biofeedback or relaxation therapy, therapist-assisted mobilisation, manual trigger point therapy, supervised postural exercise, supervised jaw exercise and stretching with or without manual trigger point therapy, and usual care (such as home exercises, stretching, reassurance, and education); (2) conditional recommendations in favour of manipulation, supervised jaw exercise with mobilisation, CBT with non-steroidal anti-inflammatory drugs (NSAIDS), manipulation with postural exercise, and acupuncture; (3) conditional recommendations against reversible occlusal splints (alone or in combination with other interventions), arthrocentesis (alone or in combination with other interventions), cartilage supplement with or without hyaluronic acid injection, low level laser therapy (alone or in combination with other interventions), transcutaneous electrical nerve stimulation, gabapentin, botulinum toxin injection, hyaluronic acid injection, relaxation therapy, trigger point injection, acetaminophen (with or without muscle relaxants or NSAIDS), topical capsaicin, biofeedback, corticosteroid injection (with or without NSAIDS), benzodiazepines, and β blockers; and (4) strong recommendations against irreversible oral splints, discectomy, and NSAIDS with opioids.
[HOW THIS GUIDELINE WAS CREATED] An international guideline development panel including patients, clinicians with content expertise, and methodologists produced these recommendations in adherence with standards for trustworthy guidelines using the GRADE approach. The MAGIC Evidence Ecosystem Foundation (MAGIC) provided methodological support. The panel approached the formulation of recommendations from the perspective of patients, rather than a population or health system perspective.
[THE EVIDENCE] Recommendations are informed by a linked systematic review and network meta-analysis summarising the current body of evidence for benefits and harms of conservative, pharmacologic, and invasive interventions for chronic pain secondary to TMD.
[UNDERSTANDING THE RECOMMENDATION] These recommendations apply to patients living with chronic pain (≥3 months duration) associated with TMD as a group of conditions, and do not apply to the management of acute TMD pain. When considering management options, clinicians and patients should first consider strongly recommended interventions, then those conditionally recommended in favour, then conditionally against. In doing so, shared decision making is essential to ensure patients make choices that reflect their values and preference, availability of interventions, and what they may have already tried. Further research is warranted and may alter recommendations in the future.
[CURRENT PRACTICE] TMD are the second most common musculoskeletal chronic pain disorder after low back pain, affecting 6-9% of adults globally. TMD are associated with pain affecting the jaw and associated structures and may present with headaches, earache, clicking, popping, or crackling sounds in the temporomandibular joint, and impaired mandibular function. Current clinical practice guidelines are largely consensus-based and provide inconsistent recommendations.
[RECOMMENDATIONS] For patients living with chronic pain (≥3 months) associated with TMD, and compared with placebo or sham procedures, the guideline panel issued: (1) strong recommendations in favour of cognitive behavioural therapy (CBT) with or without biofeedback or relaxation therapy, therapist-assisted mobilisation, manual trigger point therapy, supervised postural exercise, supervised jaw exercise and stretching with or without manual trigger point therapy, and usual care (such as home exercises, stretching, reassurance, and education); (2) conditional recommendations in favour of manipulation, supervised jaw exercise with mobilisation, CBT with non-steroidal anti-inflammatory drugs (NSAIDS), manipulation with postural exercise, and acupuncture; (3) conditional recommendations against reversible occlusal splints (alone or in combination with other interventions), arthrocentesis (alone or in combination with other interventions), cartilage supplement with or without hyaluronic acid injection, low level laser therapy (alone or in combination with other interventions), transcutaneous electrical nerve stimulation, gabapentin, botulinum toxin injection, hyaluronic acid injection, relaxation therapy, trigger point injection, acetaminophen (with or without muscle relaxants or NSAIDS), topical capsaicin, biofeedback, corticosteroid injection (with or without NSAIDS), benzodiazepines, and β blockers; and (4) strong recommendations against irreversible oral splints, discectomy, and NSAIDS with opioids.
[HOW THIS GUIDELINE WAS CREATED] An international guideline development panel including patients, clinicians with content expertise, and methodologists produced these recommendations in adherence with standards for trustworthy guidelines using the GRADE approach. The MAGIC Evidence Ecosystem Foundation (MAGIC) provided methodological support. The panel approached the formulation of recommendations from the perspective of patients, rather than a population or health system perspective.
[THE EVIDENCE] Recommendations are informed by a linked systematic review and network meta-analysis summarising the current body of evidence for benefits and harms of conservative, pharmacologic, and invasive interventions for chronic pain secondary to TMD.
[UNDERSTANDING THE RECOMMENDATION] These recommendations apply to patients living with chronic pain (≥3 months duration) associated with TMD as a group of conditions, and do not apply to the management of acute TMD pain. When considering management options, clinicians and patients should first consider strongly recommended interventions, then those conditionally recommended in favour, then conditionally against. In doing so, shared decision making is essential to ensure patients make choices that reflect their values and preference, availability of interventions, and what they may have already tried. Further research is warranted and may alter recommendations in the future.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 재료 | hyaluronic acid
|
히알루론산 | dict | 2 | |
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 1 | |
| 해부 | temporomandibular
|
scispacy | 1 | ||
| 해부 | jaw
|
scispacy | 1 | ||
| 해부 | cartilage
|
scispacy | 1 | ||
| 해부 | muscle
|
scispacy | 1 | ||
| 해부 | oral
|
scispacy | 1 | ||
| 해부 | TMD
→ temporomandibular disorders
|
scispacy | 1 | ||
| 합병증 | occlusal splints
|
scispacy | 1 | ||
| 약물 | gabapentin
|
C0060926
gabapentin
|
scispacy | 1 | |
| 약물 | acetaminophen
|
C0000970
acetaminophen
|
scispacy | 1 | |
| 약물 | capsaicin
|
C0006931
capsaicin
|
scispacy | 1 | |
| 약물 | benzodiazepines
|
C0005064
Benzodiazepines
|
scispacy | 1 | |
| 약물 | non-steroidal anti-inflammatory
|
scispacy | 1 | ||
| 약물 | corticosteroid
|
scispacy | 1 | ||
| 약물 | opioids
|
scispacy | 1 | ||
| 질환 | pain
|
C0030193
Pain
|
scispacy | 1 | |
| 질환 | temporomandibular disorders
|
C0039494
Temporomandibular Joint Disorders
|
scispacy | 1 | |
| 질환 | TMD
→ temporomandibular disorders
|
C0039494
Temporomandibular Joint Disorders
|
scispacy | 1 | |
| 질환 | musculoskeletal chronic pain disorder
|
C0009326
Collagen Diseases
|
scispacy | 1 | |
| 질환 | low back pain
|
C0024031
Low Back Pain
|
scispacy | 1 | |
| 질환 | headaches
|
C0018681
Headache
|
scispacy | 1 | |
| 질환 | earache
|
C0013456
Earache
|
scispacy | 1 | |
| 질환 | chronic pain
|
C0150055
Chronic pain
|
scispacy | 1 | |
| 질환 | occlusal splints
|
C0162528
Occlusal Splints
|
scispacy | 1 | |
| 질환 | jaw
|
scispacy | 1 | ||
| 기타 | temporomandibular joint
|
scispacy | 1 | ||
| 기타 | mandibular
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 |
MeSH Terms
Adult; Humans; Anti-Inflammatory Agents, Non-Steroidal; Chronic Pain; Hyaluronic Acid; Network Meta-Analysis as Topic; Systematic Reviews as Topic; Temporomandibular Joint Disorders
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.